A critical review of belumosudil in adult and pediatric patients with chronic graft-versus-host disease

References

• Pidala J, Kurland B, Chai X, et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD consortium. Blood. 2011;117(17):4651–4657.
   PubMed Web of Science ®Google Scholar
• Hamilton BK. Updates in chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program. 2021;2021(1):648–654.
   PubMedGoogle Scholar
• Bachier CR, Aggarwal SK, Hennegan K, et al. Epidemiology and treatment of chronic graft-versus-host disease post-allogeneic hematopoietic cell transplantation: a US Claims Analysis. Transplant Cell Ther. 2021;27(6):504.e1–.e6.
   PubMedGoogle Scholar
• Lee SJ, Nguyen TD, Onstad L, et al. Success of immunosuppressive treatments in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2018;24(3):555–562.
   PubMed Web of Science ®Google Scholar
• Saillard C, Crocchiolo R, Furst S, et al. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen. Leuk Lymphoma. 2014;55(5):1106–1112.
   PubMed Web of Science ®Google Scholar
• Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091–2101.
   PubMed Web of Science ®Google Scholar
• Arai S, Arora M, Wang T, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2015;21(2):266–274.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Kim HT, Ho VT, et al. Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant. 2006;38(4):305–310.
   PubMed Web of Science ®Google Scholar
• Yu J, Lal LS, Anderson A. Healthcare resource utilization and costs among patients with steroid-resistant chronic graft-versus-host disease in the United States: a retrospective claims database analysis. Curr Med Res Opin. 2021;37(5):755–759.
   PubMed Web of Science ®Google Scholar
• Zeiser R, Blazar BR, Longo DL. Pathophysiology of Chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017;377(26):2565–2579.
   PubMed Web of Science ®Google Scholar
• Socié G, Ritz J. Current issues in chronic graft-versus-host disease. Blood. 2014;124(3):374–384.
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981;57(2):267–276.
   PubMed Web of Science ®Google Scholar
• Filipovich AH, Weisdorf D, Pavletic S, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: i. diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945–956.
   PubMed Web of Science ®Google Scholar
• Jagasia MH, Greinix HT, Arora M, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: i. the 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21(3):389–401.e1.
   PubMed Web of Science ®Google Scholar
• Pidala J, Kim J, Anasetti C, et al. The global severity of chronic graft-versus-host disease, determined by national institutes of health consensus criteria, is associated with overall survival and non-relapse mortality. Haematologica. 2011;96(11):1678–1684.
   PubMed Web of Science ®Google Scholar
• Lee SJ. Classification systems for chronic graft-versus-host disease. Blood. 2017;129(1):30–37.
   PubMed Web of Science ®Google Scholar
• Zhao D, Young JS, Chen YH, et al. Alloimmune response results in expansion of autoreactive donor CD4 + T cells in transplants that can mediate chronic graft-versus-host disease. J Immunol. 2011;186(2):856–868.
   PubMed Web of Science ®Google Scholar
• Wilhelm K, Ganesan J, Müller T, et al. Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat Med. 2010;16(12):1434–1438.
   PubMed Web of Science ®Google Scholar
• Allen JL, Tata PV, Fore MS, et al. Increased BCR responsiveness in B cells from patients with chronic GVHD. Blood. 2014;123(13):2108–2115.
   PubMed Web of Science ®Google Scholar
• Young JS, Wu T, Chen Y, et al. Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4 + T cells that mediate autoimmune-like chronic graft-versus-host disease. J Immunol. 2012;189(1):222–233.
   PubMed Web of Science ®Google Scholar
• Srinivasan M, Flynn R, Price A, et al. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood. 2012;119(6):1570–1580.
   PubMed Web of Science ®Google Scholar
• Sakoda Y, Hashimoto D, Asakura S, et al. Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. Blood. 2007;109(4):1756–1764.
   PubMed Web of Science ®Google Scholar
• Forcade E, Paz K, Flynn R, et al. An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. JCI Insight. 2017;2(12). DOI:10.1172/jci.insight.92111.
   PubMed Web of Science ®Google Scholar
• Martires KJ, Baird K, Citrin DE, et al. Localization of sclerotic-type chronic graft-vs-host disease to sites of skin injury: potential insight into the mechanism of isomorphic and isotopic responses. Arch Dermatol. 2011;147(9):1081–1086.
   PubMedGoogle Scholar
• Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005;105(7):2973–2978.
   PubMed Web of Science ®Google Scholar
• Rozmus J, Schultz KR, Wynne K, et al. Early and late extensive chronic graft-versus-host disease in children is characterized by different Th1/Th2 cytokine profiles: findings of the children’s oncology group study ASCT0031. Biol Blood Marrow Transplant. 2011;17(12):1804–1813.
   PubMed Web of Science ®Google Scholar
• Weinberg K, Blazar BR, Wagner JE, et al. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood. 2001;97(5):1458–1466.
   PubMed Web of Science ®Google Scholar
• Sarantopoulos S, Stevenson KE, Kim HT, et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res. 2007;13(20):6107–6114.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Arora M, Defilipp Z, et al. Safety, tolerability, and efficacy of axatilimab, a CSF-1R humanized antibody, for chronic graft-Versus-host disease after 2 or more lines of systemic treatment. Blood. 2021;138(Supplement 1):263.
   Google Scholar
• Malard F, Labopin M, Yakoub-Agha I, et al. Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study. Blood. 2017;130(20):2186–2195.
   PubMed Web of Science ®Google Scholar
• Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314(12):729–735.
   PubMed Web of Science ®Google Scholar
• Cutler C, Logan B, Nakamura R, et al. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood. 2014;124(8):1372–1377.
   PubMed Web of Science ®Google Scholar
• Perkins J, Field T, Kim J, et al. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2010;16(7):937–947.
   PubMed Web of Science ®Google Scholar
• Bolaños-Meade J, Reshef R, Fraser R, et al. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol. 2019;6(3):e132–e43.
   PubMed Web of Science ®Google Scholar
• Luznik L, Pasquini MC, Logan B, et al. Randomized phase III BMT CTN trial of calcineurin inhibitor–free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies. J clin oncol. 2022;40(4):356–368.
   PubMed Web of Science ®Google Scholar
• Kröger N, Solano C, Wolschke C, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016;374(1):43–53.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98(10):2942–2947.
   PubMed Web of Science ®Google Scholar
• Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophylaxis with or without anti-T cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855–864.
   PubMed Web of Science ®Google Scholar
• Walker I, Panzarella T, Couban S, et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol. 2016;17(2):164–173.
   PubMed Web of Science ®Google Scholar
• Soiffer RJ, Kim HT, McGuirk J, et al. Prospective, Randomized, double-blind, phase iii clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-Matched unrelated myeloablative hematopoietic cell transplantation. J Clin Oncol. 2017;35(36):4003–4011.
   PubMed Web of Science ®Google Scholar
• Anasetti C, Logan BR, Lee SJ, et al. Peripheral-Blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367(16):1487–1496.
   PubMed Web of Science ®Google Scholar
• Meyer EH, Hoeg R, Moroz A, et al. Orca-T, a precision treg-engineered donor product, prevents acute gvhd with less immunosuppression in an early multicenter experience with myeloablative HLA-matched transplants. Blood. 2020;136(Supplement 1):47–48.
   Google Scholar
• Zhao Y, Shi J, Luo Y, et al. Calcineurin Inhibitors replacement by ruxolitinib as graft-versus-host disease prophylaxis for patients after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2020;26(5):e128–e33.
   PubMed Web of Science ®Google Scholar
• Gooptu M, Antin JH. GVHD Prophylaxis 2020. Front Immunol. 2021;12. DOI:10.3389/fimmu.2021.605726
   PubMed Web of Science ®Google Scholar
• Flowers MED, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015;125(4):606–615.
   PubMed Web of Science ®Google Scholar
• Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539–2549.
   PubMed Web of Science ®Google Scholar
• Miklos D, Cutler CS, Arora M, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130(21):2243–2250.
   PubMed Web of Science ®Google Scholar
• Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29(10):2062–2068.
   PubMed Web of Science ®Google Scholar
• Zeiser R, Polverelli N, Ram R, et al. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med. 2021;385(3):228–238.
   PubMed Web of Science ®Google Scholar
• Modi B, Hernandez-Henderson M, Yang D, et al. Ruxolitinib as salvage therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2019;25(2):265–269.
   PubMed Web of Science ®Google Scholar
• Biswas PS, Gupta S, Chang E, et al. Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J Clin Invest. 2010;120(9):3280–3295.
   PubMed Web of Science ®Google Scholar
• Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, et al. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A. 2014;111(47):16814–16819.
   PubMed Web of Science ®Google Scholar
• Tengesdal IW, Kitzenberg D, Li S, et al. The selective ROCK2 inhibitor KD025 reduces IL-17 secretion in human peripheral blood mononuclear cells independent of IL-1 and IL-6. Eur J Immunol. 2018;48(10):1679–1686.
   PubMed Web of Science ®Google Scholar
• Flynn R, Paz K, Du J, et al. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016;127(17):2144–2154.
   PubMed Web of Science ®Google Scholar
• Riches DW, Backos DS, Redente EF. ROCK and Rho: promising therapeutic targets to ameliorate pulmonary fibrosis. Am J Pathol. 2015;185(4):909–912.
   PubMed Web of Science ®Google Scholar
• Jagasia M, Lazaryan A, Bachier CR, et al. ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease. J clin oncol. 2021;39(17):1888–1898. https://rezurockhcp.com/full-prescribing-information.pdf.
   PubMed Web of Science ®Google Scholar
• Cutler C, Lee SJ, Arai S, et al. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar study. Blood. 2021;138(22):2278–2289.
   PubMed Web of Science ®Google Scholar